Biliary tract cancers (BTC) are a diverse group of tumours that arise from the biliary tract epithelium. Biliary tract cancers can be divided into three major clinical phenotypes: cholangiocarcinomas (CC) of intrahepatic (ICC) and extrahepatic (ECC) origin and adenocarcinomas of the gallbladder (GBAC). In the United States and Europe, risk factors for BTC include chronic biliary tract diseases, such as primary sclerosing cholangitis, hepatolithiasis, choledochal cysts, and other anatomical malformations of the bile ducts ([@bib1]). Non-biliary diseases such as heavy alcohol abuse, obesity, non-alcoholic fatty liver disease, chronic hepatitis C, and cirrhosis are also more prevalent in BTC patients compared with the general population. For BTC patients with locally advanced or metastatic disease, the prognosis is poor with median survival less than 1 year ([@bib17]). Common therapeutic options include surgery and chemotherapy but as BTC patients often present in an unresectable state, there is an urgent need of novel chemotherapeutic options ([@bib31]). As some BTC patients are in a general condition insufficient to undergo aggressive systemic treatment, finding better and reliable prognostic markers for BTC is of importance for further stratification of patients for therapeutic trials.

Tumour cells are often surrounded by infiltrating inflammatory cells, particularly lymphocytes and macrophages ([@bib41]). Tumour antigens drive the development of tumour-specific adaptive immune responses ([@bib2]). CD4+ and CD8+ T lymphocytes are crucial components of tumour-specific cellular adaptive immunity. CD8+ T lymphocytes attack tumour cells presenting tumour-associated antigen peptide with major histocompatibility complex class I (MHC I) on their surface by producing interferon-*γ*. Interferon-*γ*-dependent mechanisms of tumour cell cytostasis and killing comprise cell cycle inhibition, apoptosis, angiostasis, and induction of antitumourigenic activity of macrophages ([@bib10]). Immunohistochemical studies have found that tumour-infiltrating CD8+ T lymphocytes have a favourable effect on patient survival in several malignant tumours including colorectal ([@bib13]), ovarian ([@bib46]), breast ([@bib24]), and pancreatic ([@bib12]) cancer. In colorectal cancer (CRC), density and location of CD8+ T lymphocytes have a prognostic value superior to and independent of the International Union Against Cancer (UICC) -- TNM classification ([@bib27]). Further, density of immune cells at the invasive margin of metastatic CRC is predictive for response to chemotherapy ([@bib15]).

In BTC, sub-populations of immune cells have so far only been studied in parts, using comparably small patient cohorts and without specifying anatomical/histological subtypes ([@bib30]; [@bib42]). Therefore, our aim was to analyse the influence of density and distribution of tumour-infiltrating immune cells on patient prognosis in a large, well-characterized series of BTC patients with long-time follow-up.

Materials and methods
=====================

Clinicopathological characteristics of BTC patients
---------------------------------------------------

Tissue samples from 375 patients (median 64.1 years) who underwent bile duct and/or liver surgery at the University Hospital Heidelberg between 1995 and 2010 were included in this study. Only patients with primary adenocarcinomas of the biliary tract and without other known malignancies at the time of diagnosis were included. Biliary tract cancers consisted of 149 ECC (106 perihilar and 43 distal), 157 ICC, and 69 GBAC. Patients who received radiochemotherapy before surgery were excluded. Survival data were available for 335 patients ([Table 1](#tbl1){ref-type="table"}). Tumours were restaged according to the seventh TNM classification of malignant tumours and classified after the World Health Organization (WHO) tumour classification system ([@bib3]). Clinicopathological data of the complete study cohort is given in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. The use of the tissues for this study was approved by the institutional ethics committee (206/05).

TMA construction and immunohistochemistry
-----------------------------------------

From all 375 BTC, 3 *μ*m sections were cut and stained with H&E. Representative areas from the tumour centre and invasive margins were marked by pathologists with special expertise in BTC pathology (BG and WW). For each case, tumour tissue cores (1.5 mm diameter) from the selected representative tumour areas were punched out of the sample tissue blocks and embedded into a new paraffin array block using a tissue microarrayer (Beecher Instruments, Woodland, CA, USA). For 92 cases, in addition, high-grade dysplastic lesions (BilIN III) were sampled. In addition, we included 30 metastatic lesions of BTC. For the characterisation of the inflammatory components, vessel density, and proliferative activity, a monoclonal mouse IgG antibody directed against CD4 (1:20, Novocastra, Newcastle upon Tyne, UK), a monoclonal mouse IgG antibody directed against CD8 (1:150, DAKO, Hamburg, Germany), a monoclonal mouse IgG antibody directed against CD20 (1:150, DAKO, Glostrup, Denmark), a monoclonal mouse IgG antibody directed against CD31 (1: 25, DAKO, Denmark), a monoclonal mouse IgG antibody directed against CD68 (1: 8000, DAKO, Denmark), a polyclonal rabbit IgG antibody directed against CD117 (1: 50, DAKO, Denmark), a monoclonal mouse IgG antibody directed against Perforin (1:20, Novocastra), a monoclonal IgG antibody directed against Foxp3 (1:100, clone 236A/E7, Abcam, Cambridge, UK), and a monoclonal mouse IgG antibody directed against Ki-67 (1: 200, clone Mib 1, DAKO, Glostrup, DK) were used. Staining was performed on two automated systems (Foxp3: Bond, Leica, Wetzlar, Germany; all others were obtained from Discovery Ultra, Ventana, Tuscon, AZ, USA) following the manufacturers\' instructions.

Evaluation of TMAs
------------------

Immune cell density was assessed quantitatively on tissue microarray (TMA) slides. Immune cells were identified as either T-helper cells (CD4+), regulatory T lymphocytes (Foxp3+, a subset of CD4+ T lymphocytes), cytotoxic T lymphocytes (CD8+), natural killer (NK) cells (perforin+), B lymphocytes (CD20+), macrophages (CD68+), and mast cells (CD117+). The immunostaining was in all instances evaluated in conjunction with morphology to avoid misclassification of immunohistochemically positive cells without matching morphology as immune cells. For CD4, CD8, CD20, CD68, Foxp3, CD31, and Ki-67 the whole set of cases could be evaluated, whereas for perforin and CD117 only a part of the cohort was available. Infiltrating immune cells were numerically evaluated in the category 'total\' by counting the total number of positive immune cells per TMA dot, regardless of whether these cells were found in the epithelial or in the stromal compartment of the adenocarcinoma (for example, 'CD4 total\'). For statistical analyses, the cases were grouped by using the median as a cutoff. We defined those cases with an inflammatory infiltrate above the median as positive and those cases with an inflammatory infiltrate below the median as negative for the respective infiltrating immune cell type. Overall, NK cell count numbers were very low; therefore, we grouped cases as having none or any number of infiltrating NK cells. In solid tumours, the localisation of inflammatory cells (stroma *vs* epithelium) has been shown to be of some importance ([@bib13]). Therefore, the number of infiltrating immune cells within a representative area containing 100 carcinoma cells (epithelial compartment of the carcinoma) was evaluated separately (for example, 'CD4 intraepithelial\'). Immune cells observed in lymphoid follicles (aggregates) were excluded from counting; the presence of lymph follicles was evaluated separately. For technical reasons, single TMA dots could not be evaluated with the necessary precision. Therefore, the number of cases included varies between the statistical analyses of the different immune cell types. The number of Ki-67-stained tumour cells out of 100 tumour cells were counted and expressed in percent. The number of CD31+ vessels was counted per TMA dot (1.5 mm diameter).

Statistical analyses
--------------------

Statistical analyses were performed with the statistical computing environment R version 2.15.1 and IBM SPSS STATISTICS version 19 (SPSS, Chicago, IL, USA). Spearman\'s rank order correlation was used to determine whether there was a positive or negative correlation between the degrees of tumour-infiltrating immune cells, vessel density, and proliferative activity. The significance of differences in the density of immune cells for differing tumour stages and other clinicopathological variables was assessed with Mann--Whitney-*U*-tests, Kruskal--Wallis tests, and *χ*^2^-tests, as indicated. Statistically significant trends associated with increasing UICC stages, tumour grades, or T-stages were identified by Jonkheere--Terpstra and Cochran--Armitage trend tests. Univariate survival analysis was performed for overall survival by generation of Kaplan--Meier curves. Significance of differences between the groups was assessed using the log-rank test. For multivariate analysis, concordance regression ([@bib9]) was applied, representing a generalisation of Cox proportional hazards regression, which is robust to violations of the proportional hazards assumption. *P*-values\<0.05 were considered significant. All tests were done two sided.

Results
=======

Characteristic distribution of inflammatory infiltrate in BTC
-------------------------------------------------------------

In BTC, T lymphocytes were the most prevalent inflammatory cell type (for exemplary photomicrographs, see [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). The majority of T lymphocytes were CD8+ T lymphocytes (64 cells per TMA spot) but CD4+ T lymphocytes were also frequently found (40 cells per spot; [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Correspondingly, CD8+ T lymphocytes showed a higher propensity towards infiltration of tumour epithelium (48.4% of cases), whereas only 36.3% of cases had intraepithelial CD4+ T lymphocyte infiltrates ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Of the CD4+ T lymphocytes, only a subset was of the Foxp3+ regulatory T-cell-type (in median 5 out of 40, 12.5%, [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). B lymphocytes were only infrequently observed. More than half of the tumours did not show any B lymphocyte infiltrate and only 1.4% of BTC showed B lymphocytes within the tumour epithelium ([Supplementary Tables 1 and 2](#sup1){ref-type="supplementary-material"}).

Macrophages were quite frequently encountered per total TMA dot (median of 72 cells) as well as in the tumour epithelium (77.6% of cases). Mast cells were infrequently seen with more than half of the tumours being completely negative. Within the tumour epithelium, mast cells were infrequent as well (4.3% of cases; [Supplementary Tables 1 and 2](#sup1){ref-type="supplementary-material"}). Total NK cell count was very low, with only 19.1% of tumours showing any infiltration of this cell type at all ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}).

The total count of CD4+ T lymphocytes, CD8+ T lymphocytes, regulatory T lymphocytes, B lymphocytes, and mast cells was high in BilIN III, and showed a stepwise decrease in invasive tumours and their metastases ([Figure 1](#fig1){ref-type="fig"}). Similarly, NK cell content also decreased from BilIN III to the primary tumour ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). On the contrary, the number of macrophages was increased in invasive tumours and metastases when compared with BilIN III ([Figure 1](#fig1){ref-type="fig"}).

The densities of specific immune cell types are correlated with each other and are partly associated with vessel density and proliferative activity
---------------------------------------------------------------------------------------------------------------------------------------------------

As expected, the total density of specific immune cell types was significantly correlated with the corresponding number of intraepithelial immune cells for all cell types evaluated ([Figure 2](#fig2){ref-type="fig"}). However, the statistical strength of correlations varied. Although for CD4+ T lymphocytes, CD8+ T lymphocytes, and macrophages strong correlations showing *r*-values well above 0.5 were observed, total and intraepithelial Foxp3+ regulatory T lymphocyte counts showed only a moderate association (*r*=0.41). This association was even weaker for B lymphocytes and mast cells (*r*=0.20 and *r*=0.24, respectively). The densities of CD4+ T lymphocytes, CD8+ T lymphocytes, and macrophages was quite strong, positively linked to each other, whereas the density of B lymphocytes, NK cells, and mast cells seemed to be independent. The total density of cytotoxic T cell, regulatory T lymphocytes, and macrophages was positively associated with proliferative capacity. This was also observed for intraepithelial infiltrates of regulatory T lymphocytes. All other inflammatory components did not correlate with the proliferation status. In general, the density of inflammatory cells was higher in tumours with a high microvessel count, but the respective associations of inflammatory cell numbers with vessel density were only weak ([Figure 2](#fig2){ref-type="fig"}).

Differences in the density of inflammatory infiltrate with respect to clinicopathological parameters and BTC subtypes
---------------------------------------------------------------------------------------------------------------------

Apart from the total infiltration of regulatory and cytotoxic T lymphocytes, which was higher in older patients, age and sex were not associated with significant differences in the density of inflammatory cells ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Higher UICC stages (specifically stage III) were associated with a modest increase in mast cell infiltrates ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). In contrast, NK cell counts decreased by trend in locally more advanced tumours ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Regarding the intraepithelial density of inflammatory cells, a decrease of intraepithelial CD4+ T lymphocyte density with increasing UICC and pT stages ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}) was observed. Total densities of CD4+ T lymphocytes, CD8+ T lymphocytes as well as B lymphocytes (single cells as well as aggregates) were significantly higher in low-grade than in high-grade tumours ([Supplementary Tables 1 and 2](#sup1){ref-type="supplementary-material"}; [Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). Striking differences in the composition of inflammatory cells were noted for BTC subtypes. Although ECC and GBAC showed equal amounts of total CD8+ T lymphocytes (median 88 per TMA dot; [Supplementary Table 1](#sup1){ref-type="supplementary-material"}), numbers in ICC were significantly reduced (median 40 per TMA dot, *P*\<0.001). Regulatory T lymphocytes were most frequent in GBAC (median 24 per TMA dot), followed by ECC (median 8 per TMA dot), and most infrequent in ICC (median 2 per TMA dot, *P*\<0.001; [Supplementary Table 1](#sup1){ref-type="supplementary-material"}, [Figure 3](#fig3){ref-type="fig"}). In addition, mast cell counts were higher in ECC when compared with GBAC and ICC (median 20 *vs* 0, and 0 per TMA dot, *P*\<0.001). However, these differences in total density did not translate into differences in the intraepithelial component for all cell types ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}).

The number of intraepithelial lymphocytes is an independent predictor of patient survival in BTC
------------------------------------------------------------------------------------------------

Classical survival prognosticators such as UICC stage and others proved to have high prognostic impact on our BTC cohort ([Table 1](#tbl1){ref-type="table"}). The presence of intraepithelial tumour-infiltrating CD4+ T lymphocytes as well as CD8+ T lymphocytes correlated significantly with a longer overall survival in BTC patients (*P*=0.002 and 0.015, respectively). Patients who had higher total regulatory T lymphocyte counts had a significantly better prognosis when compared with those patients whose tumour tissues showed lower regulatory T-lymphocyte counts ([Figure 4F](#fig4){ref-type="fig"}, *P*=0.018). Intraepithelial B lymphocytes were rarely observed and the few cases with intraepithelial cells did not differ with respect to prognosis. However, presence of total B lymphocytes had a positive prognostic impact ([Figure 4H](#fig4){ref-type="fig"}, *P*=0.032). The presence of B-lymphocyte aggregates, macrophages, or mast cells either total or within the tumour epithelium was not associated with significant differences in overall survival ([Figure 4](#fig4){ref-type="fig"}). Multivariate analysis under inclusion of UICC stage and tumour grade revealed a significant independent prognostic impact of the presence of either intraepithelial Foxp3+ regulatory T lymphocytes (HR: 0.492, *P*=0.002; [Supplementary Table 3](#sup1){ref-type="supplementary-material"}) or intraepithelial CD4+ T lymphocytes (HR: 0.595, *P*=0.008; [Supplementary Table 4](#sup1){ref-type="supplementary-material"}) but not of intraepithelial CD8+ T lymphocytes (HR: 0.840, *P*=0.363; data not shown) or total B lymphocytes (HR: 0.758, *P*=0.151; data not shown).

The role of CD4+ and CD8+ T lymphocytes as a predictor of patient survival is subtype dependent in BTC
------------------------------------------------------------------------------------------------------

We analysed the impact of immune cells on survival regarding the major subtypes of BTC and found that the prognostic significance of the presence of intraepithelial T and B lymphocytes is dependent on the BTC subtype. Our data showed that in ECC and GBAC, the respective associations of lymphocyte infiltration and prognosis were retained for CD4+ T lymphocytes ([Supplementary Figure 4](#sup1){ref-type="supplementary-material"}), CD8+ T lymphocytes ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}), regulatory T lymphocytes ([Supplementary Figure 6](#sup1){ref-type="supplementary-material"}), and B lymphocytes ([Supplementary Figure 7](#sup1){ref-type="supplementary-material"}). In contrast to ECC and GBAC, all of these prognostic parameters lost their power in the subgroup of ICC ([Supplementary Figures 4--7](#sup1){ref-type="supplementary-material"}).

Discussion
==========

In this study, we provide a comprehensive analysis of the inflammatory infiltrate in BTC by evaluating total and intraepithelial tumour-infiltrating CD4+, CD8+, Foxp3+, CD20+ lymphocytes, perforin+ NK cells, CD68+ macrophages, and CD117+ mast cells in a large and well-characterized BTC cohort. We decided not to include granulocytes in the analysis, as tumour infiltration by this cell type is heavily influenced by the presence of tumour cell necrosis and therefore difficult to analyse with respect to its biological relevance in a study design like ours.

We observed that general components of the adaptive immune response (T/B lymphocytes) decreased via the dysplasia -- primary carcinoma -- metastasis sequence, whereas components of the innate immune response (such as macrophages) increased. This observation is in line with a variety of functional data showing that in the course of carcinogenesis, neoplasms are able to learn how to evade an activation of the adaptive immune response ([@bib10]; [@bib32]).

In general, we observed that the adaptive immune response is beneficial for BTC patients and its activation is associated with longer overall survival times. In line with these results, some of the inflammatory cell types involved in this type of immune response have previously been linked to a more favourable outcome in other malignancies ([@bib6]; [@bib12]; [@bib13]; [@bib24]; [@bib27]). An explanation for this association is that these inflammatory cells represent a cell-mediated immune response against the tumour. However, the particular tumour-infiltrating immune cell type relevant for patient outcome may vary between different malignancies.

The role of CD8+ T lymphocytes in tumour progression has been examined in a variety of human malignancies ([@bib30]; [@bib12]; [@bib13]; [@bib24]; [@bib27]). Most of these studies reported a beneficial prognostic effect of high intratumoural/intraepithelial CD8+ T lymphocyte counts -- a finding, which we were able to expand to BTC in the present study. The role of CD4+ T lymphocytes in immunologic anticancer response is more controversial. It is generally accepted that CD4+ T lymphocytes may suppress tumour growth indirectly through cytokine production ([@bib43]). However, a low CD4/CD8 ratio has also been reported to be associated with better prognosis of patients in colorectal carcinoma ([@bib7]), suggesting an adverse effect of CD4+ T lymphocytes on the ability of CD8+ T lymphocytes to attack tumours in certain conditions. On the other hand, cooperation between CD4+ and CD8+ T lymphocytes has been described to improve patient outcome ([@bib6]). We found a favourable prognostic impact of both intraepithelial tumour-infiltrating CD4+ and CD8+ T lymphocytes indicating a cooperative antitumour effect of these two T lymphocyte types in BTC.

Tumour cells can suppress immunity either by producing immunosuppressive molecules or by attracting other immune cell types, which in turn are able to suppress the immune reaction against the tumour. The latter mode of action has been suggested to be mediated at least in part by regulatory T lymphocytes ([@bib47]; [@bib23]). However, infiltration of regulatory T lymphocytes *in vivo* has been observed to be associated with inconsistent survival probabilities ([@bib39]; [@bib40]; [@bib25]; [@bib45]). In this BTC cohort, total tumour-infiltrating regulatory T lymphocytes were associated with a longer patient survival. Therefore, a prognostically relevant immunosuppressive effect of regulatory T lymphocytes is unlikely in BTC.

The functional contribution of B lymphocytes to the inflammatory response of solid tumours is not well understood. Here we present data that showed that the total tumour-infiltrating B lymphocyte count is correlated with a longer overall survival probability in BTC. Whether this observation just reflects an epiphenomenon in the context of immune response activation, or whether it is indicative of a true contribution of B lymphocytes to tumour control by the immune system should be determined in future studies.

Our data revealed that ECC, GBAC, and ICC are different regarding the prognostic importance of the inflammatory infiltrate. Although all three BTC subtypes are traditionally merged in the clinical context and are treated similarly with respect to chemotherapeutic approaches, there is evidence that this viewpoint might be oversimplified concerning the molecular basis of the BTC subtypes ([@bib14]; [@bib5]; [@bib21]). The here-observed subtype-specific immune responses and their differing associations with patient survival suggest profound differences in the immune system -- tumour interaction for the respective BTC subtypes. In this regard, one potentially important mechanism might be tumour immune escape. Immune escape mechanisms of tumour cells have been studied extensively in a variety of human cancers, including breast, prostate, pancreatic, oesophagus, and CRC ([@bib8]; [@bib35]). However, concerning biliary malignancies and immune escape mechanisms, the number of available studies is limited. One major mechanism of immune escape is the downregulation of MHC I antigen on cancer cells by a number of different molecular alterations ([@bib36]; [@bib37]). Down-regulation of MHC I expression on cancer cells has been shown in a variety of human malignancies and mostly, but not exclusively, had a negative impact on patient survival ([@bib28]; [@bib11]; [@bib26]; [@bib29]; [@bib16]; [@bib19]; [@bib8]). Further, the correct function of MHC I antigen is dependent on a network of intracellular proteins called the antigen-processing machinery (APM). We could recently demonstrate that besides down-regulation of MHC I, down-regulation of other components of the APM is also linked to the density of tumour-infiltrating lymphocytes and also correlates with poor patient survival in CRC ([@bib19]). Such mechanisms might be underlying the failure of antitumour inflammation to improve prognosis in ICC observed in our study. This theory is strengthened by proposed differences for the cell of origin of ICC and ECC/GBAC. Although recently developed concepts of a stem cell phenotype in hepatocellular carcinoma/combined hepatocellular CC show stem cell features that are also encountered in classical ICC, the hilar/distal ECC and GBAC show a different stem cell phenotype originating from biliary tree stem cells ([@bib3]; [@bib34]; [@bib21]). It is known that several normal and cancer stem cells express minimal or no class I and II MHC ([@bib22]; [@bib8]). This knowledge has specifically been confirmed in human hepatic stem cells ([@bib22]; [@bib33]). This might explain why ICC are able to evade damage induced by tumour immune response, which in turn would explain the missing association of inflammation and ameliorated patient outcome in this tumour subtype. However, further studies are necessary to prove that alterations in MHC-associated mechanisms are actually of importance in BTC. Another potential mechanism of tumour immune escape is Fas-mediated apoptosis of immune cells. Fas ligand (FasL) binding to death receptor Fas triggers apoptosis of Fas-expressing cells including tumour-infiltrating immune cells. Upregulation of FasL has been demonstrated in a variety of human neoplasms and was linked to survival ([@bib8]). In ICC, one study showed upregulation of FasL at early stages and downregulation of FasL at progressed stages, thereby indicating a potential role of this immune escape mechanism in cholangiocarcinogenesis ([@bib38]). Interestingly, *in vitro* experiments showed that primary and malignant cholangiocytes undergo CD40-mediated Fas-dependent apoptosis, but are insensitive to direct activation with exogenous FasL ([@bib18]).

Recently, immune response modulating targeted drugs have been successfully tested as anticancer agents in a variety of human tumours ([@bib44]; [@bib4]; [@bib20]). As the clinical effect of these drugs is now explored in other neoplasias, our data may serve as a rationale to launch future clinical trials in BTC patients.

In conclusion, we report that the presence of both intratumoural T and B lymphocytes is correlated with a longer survival in BTC patients. In addition, we found that BTC subtypes show important differences in the composition and the prognostic relevance of immune cell infiltrate, that is, in ECC and GBAC, prognosis was inflammation linked, whereas in ICC no such association was observed. These data provide a solid basis for a better understanding of the biological role of inflammatory infiltrate in BTC and might therefore encourage future functional and clinical studies exploring the modulation of the inflammatory response for the benefit of BTC patients.
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![**Distribution of inflammatory cell infiltrates in non-invasive precursors (BilIN III), tumour margin, tumour centre, and metastatic lesions of BTC.** Total number of CD4+ T lymphocytes (**A**), Foxp3+ regulatory T lymphocytes (**B**), CD8+ T lymphocytes (**C**), CD20+ B lymphocytes (**D**), CD68+ macrophages (**E**), CD117+ mast cells (**F**) in non-invasive precursors (BilIN III), tumour margin, tumour centre, and metastatic lesions of BTC.](bjc2013610f1){#fig1}

![**Spearman\'s correlation between all assessed inflammatory parameters.** Colours of cubes represent strength of correlation, with dark colours showing a high degree of association. In each cube, there are three values given: top=r, middle=p, and bottom=n.](bjc2013610f2){#fig2}

![**Distribution of inflammatory cell infiltrates in biliary tract cancers (BTC) and subtypes.** Total number of CD4+ T lymphocytes (**A**), CD8+ T lymphocytes (**B**), Foxp3+ regulatory T lymphocytes (**C**), CD20+ B lymphocytes (**D**), CD68+ macrophages (**E)**, and CD117+ mast cells (**F**) in BTC, extrahepatic cholangiocarcinoma (ECC), adenocarcinoma of the gallbladder (GBAC), and intrahepatic cholangiocarcinoma (ICC).](bjc2013610f3){#fig3}

![**Overall survival probability in BTC patients stratified for inflammatory cell infiltrates.** Kaplan--Meier curves depict overall survival probability stratified for either intraepithelial (**A**, **C**, **E**, **I**, **K**) or total (**B**, **D**, **F**, **G**, **H**, **J**, **L**) immune cell infiltrate of CD4+ T lymphocytes (**A**, **B**), CD8+ T lymphocytes **(C**, **D),** Foxp3+ regulatory T lymphocytes (**E**, **F**). CD20+ B lymphocytes **(G**, **H)**, CD68+ macrophages (**I**, **J**), and CD117+ mast cells (**K**, **L**). *P*-values were calculated with a log-rank test.](bjc2013610f4){#fig4}

###### Overall survival in dependence of clinicopathological parameters and inflammatory cell infiltrate

                               **Number of cases**   **Number of events**   **Median survival (months)**   **Confidence interval**   ***P*****-value**
  --------------------------- --------------------- ---------------------- ------------------------------ ------------------------- -------------------
  **All cases**                                                                                                                     
                                       335                   240                       21.78                   (17.94--26.45)                 
  **Age**                                                                                                                           
  64--92 years                         161                   119                       22.01                   (15.84--28.94)              0.358
  31--63.9 years                       174                   121                       21.39                   (17.51--29.86)                 
  **Sex**                                                                                                                           
  M                                    175                   126                       17.74                   (14.29--25.53)              0.213
  W                                    160                   114                        24.8                    (20.7--33.31)                 
  **BTC subgroups**                                                                                                                 
  ICC                                  148                   105                       21.39                   (17.45--28.94)              0.565
  ECC                                  143                   102                       24.84                   (18.99--35.19)                 
  GBAC                                 44                     33                       17.12                    (9.76--31.7)                  
  **Histology subgroups**                                                                                                           
  Ductal                               272                   198                       21.78                   (17.74--26.45)             \<0.001
  Papillary                            22                     11                       74.64                     (21.45-NA)                   
  Mucinous                              7                     3                         31.7                     (20.86-NA)                   
  Intestinal                           10                     6                        34.66                     (17.12-NA)                   
  Other                                17                     16                        6.28                    (3.19--48.76)                 
  **UICC**                                                                                                                          
  UICC I                               38                     20                       37.45                     (24.67-NA)               \<0.001
  UICC II                              71                     42                       35.19                    (23.1--65.48)                 
  UICC III                             73                     61                       14.49                   (10.55--30.32)                 
  UICC IV                              83                     67                       11.37                    (9.2--17.74)                  
  **pT**                                                                                                                            
  T1                                   73                     47                       27.93                   (18.46--53.62)             \<0.001
  T2                                   131                    90                       26.09                    (20.7--38.24)                 
  T3                                   103                    81                       16.92                   (11.76--23.59)                 
  T4                                   28                     22                        8.89                    (6.51--45.34)                 
  **pN**                                                                                                                            
  N0                                   120                    73                       36.63                   (24.67--49.45)             \<0.001
  N1                                   142                   114                       14.09                   (10.71--18.99)                 
  **M**                                                                                                                             
  M0                                   321                   227                        22.8                    (18.6--27.66)              0.004
  M1                                   14                     13                        9.72                      (7.16-NA)                   
  **G**                                                                                                                             
  G1                                   19                     13                       30.16                     (11.63-NA)               \<0.001
  G2                                   231                   158                       27.66                   (21.45--36.73)                 
  G3                                   85                     69                       12.48                   (10.32--18.53)                 
  **L**                                                                                                                             
  L0                                   154                    98                       35.61                   (24.67--48.39)             \<0.001
  L1                                   181                   142                       15.21                   (11.63--21.39)                 
  **V**                                                                                                                             
  V0                                   247                   175                        22.8                   (18.83--29.86)              0.081
  V1                                   88                     65                       14.62                   (10.71--28.94)                 
  **Pn**                                                                                                                            
  Pn0                                  258                   178                       23.39                    (18.53--31.9)              0.012
  Pn1                                  77                     62                       17.22                    (13.8--24.84)                 
  **R**                                                                                                                             
  R0                                   155                    93                       35.68                   (24.67--49.45)             \<0.001
  R1                                   137                   113                       17.12                   (12.48--22.01)                 
  R2                                   18                     15                        9.13                    (6.51--24.8)                  
  RX                                   25                     19                       20.86                   (12.71--53.88)                 
  **CD4 intraepithelial**                                                                                                           
  None                                 196                   152                       18.99                    (15.21--24.8)              0.002
  Any                                  113                    68                       35.61                    (21.78--50.5)                 
  **Foxp3 intraepithelial**                                                                                                         
  None                                 270                   199                       20.86                   (17.41--24.84)              0.256
  Any                                  39                     25                       27.93                   (10.84--110.42)                
  **CD8 intraepithelial**                                                                                                           
  None                                 162                   131                       20.27                    (16.92--24.8)              0.015
  Any                                  152                    94                       27.66                    (18.99--48.3)                 
  **CD20 intraepithelial**                                                                                                          
  None                                 318                   229                       22.18                   (18.46--26.74)              0.533
  Any                                   5                     3                        25.59                     (15.38-NA)                   
  **CD68 intraepithelial**                                                                                                          
  None                                 70                     55                       18.83                    (13.8--26.48)              0.122
  Any                                  246                   173                        23.1                   (18.53--30.62)                 
  **CD117 intraepithelial**                                                                                                         
  None                                 156                   107                       22.41                   (17.22--35.19)              0.152
  Any                                   7                     2                          /                        (9.56-NA)                   
  **CD4 total**                                                                                                                     
  ⩽Median                              161                   124                       20.86                   (16.92--25.53)              0.079
  \>Median                             148                    96                       27.93                   (17.74--40.31)                 
  **Foxp3 total**                                                                                                                   
  ⩽Median                              156                   120                       16.92                   (12.48--22.01)              0.018
  \>Median                             153                   104                       25.59                   (20.86--38.51)                 
  **CD8 total**                                                                                                                     
  ⩽Median                              165                   129                       20.27                   (17.12--24.84)              0.129
  \>Median                             149                    96                       25.59                   (17.74--40.21)                 
  **Perforin total**                                                                                                                
  None                                 147                    98                       21.78                    (15.38--36.5)              0.261
  Any                                  36                     23                       28.06                   (21.39--136.84)                
  **CD20 total**                                                                                                                    
  ⩽Median                              173                   129                        18.6                   (16.13--24.67)              0.032
  \>Median                             150                   103                       25.59                    (20.8--43.1)                  
  **CD20 aggregate**                                                                                                                
  None                                 312                   222                       20.86                   (17.45--25.53)              0.93
  Any                                  23                     18                       30.32                   (22.41--55.62)                 
  **CD68 total**                                                                                                                    
  ⩽Median                              161                   120                       20.86                   (17.45--27.66)              0.62
  \>Median                             155                   108                       24.51                   (17.41--33.31)                 
  **CD117 total**                                                                                                                   
  ⩽Median                              83                     61                       20.01                    (14.92--36.5)              0.171
  \>Median                             80                     48                       25.59                   (18.99--53.88)                 

Abbreviations: BTC=biliary tract cancer; ECC=extrahepatic cholangiocarcinoma; GBAC=gallbladder adenocarcinoma; ICC=intrahepatic cholangiocarcinoma; M=man; UICC=Union for International Cancer Control; W=woman.

Patients without adequate follow-up data were not included. Single parameters were not evaluable in all patients. *P*-values were calculated with a log-rank test.
